Last reviewed · How we verify
NCT06892691: PERFECT-MPE
Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions
NA trial testing Pleuroscopy first in Pleural Effusion in 98 participants. Currently enrolling.
17 September 2026
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 98 |
| Start date | 24 March 2025 |
| Primary completion | 17 September 2026 |
| Estimated completion | 17 September 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Pleuroscopy first
- Thoracentesis first
Conditions studied
- Pleural Effusion — all drugs for Pleural Effusion →
- Cancer — all drugs for Cancer →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with Pleural Effusion or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06892691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pleural Effusion
Currently open trials in the same condition.
- NCT07248774 — Effect of Bubble Positive Expiratory Pressure and Segmental Breathing Versus Incentive Spirometry in Pleural Effusion · NA · recruiting
- NCT07012759 — Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients · recruiting
- NCT06958848 — 16F vs 24F Chest Drain After Minimally Invasive Lobectomy and/or Segmentectomy · NA · recruiting
- NCT06314620 — Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency · NA · recruiting
- NCT06247800 — Virtual Reality: Distraction During Small Bore Intercostal Chest Drain Insertion · NA · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06892691 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06892691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing